Company Description
Intelligent Medical Objects (“IMO”) is a rapidly growing software, technology, and content provider of a rich set of clinical interface terminology products used by clinicians at the point of care to most accurately capture, measure, and maintain the “true” clinical intent during patient encounters. IMO’s solutions provide the data interoperability and source of truth required to enable communication between clinicians, patients, information technology platforms, and all downstream data use cases. Meaningful Use standards and the shift to ICD-10 have put significant strain on providers to capture the diagnosis at the most granular level possible, driving a significant need for IMO’s suite of solutions. Off the back of these market pressures, IMO has established itself as the clear market leader, placing its products in over 50% of all US hospitals and with over 25% of ambulatory physicians.
Objectives
TripleTree was engaged by IMO to evaluate its strategic alternatives and to find a partner that would support the unique value proposition and exceptional growth opportunities of the business. TripleTree was chosen as the exclusive advisor to IMO based on a deep understanding of many inter-related and highly complex healthcare industry drivers (e.g., MU, ICD-10, data analytics, value-based reimbursement, etc.). TripleTree successfully conveyed IMO’s value proposition by highlighting the Company’s unique ability to provide the infrastructure that powers a vast range of use current and future use cases for clinical data.
Results
In a competitive process, IMO realized a successful growth investment by Warburg Pincus, who were attracted to IMO’s exceptional recurring revenue, entrenched and unrivaled market position, and strong customer relationships. Warburg Pincus distinguished itself through its deep industry experience, strong ties within the healthcare industry and vision for the future of the company.
BACK TO TRANSACTIONS